Mary H Samuels1, Irina Kolobova2, Megan Antosik3, Meike Niederhausen4, Jonathan Q Purnell5, Kathryn G Schuff1. 1. Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University, Portland, Oregon 97239. 2. Penn State Health St. Joseph Family Medicine Residency, Reading, Pennsylvania 19603. 3. Legacy Emanuel Medical Center, Portland, Oregon 97227. 4. Biostatistics & Design Program, Oregon Health & Science University-Portland State University School of Public Health, Portland, Oregon 97239. 5. Knight Cardiovascular Institute, Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University, Portland, Oregon 97239.
Abstract
Purpose: It is not clear whether upper limits of the thyrotropin (TSH) reference range should be lowered. This debate can be better informed by investigation of whether variations in thyroid function within the reference range have clinical effects. Thyroid hormone plays a critical role in determining energy expenditure, body mass, and body composition, and therefore clinically relevant variations in these parameters may occur across the normal range of thyroid function. Methods: This was a cross-sectional study of 140 otherwise healthy hypothyroid subjects receiving chronic replacement therapy with levothyroxine (L-T4) who had TSH levels across the full span of the laboratory reference range (0.34 to 5.6 mU/L). Subjects underwent detailed tests of energy expenditure (total and resting energy expenditure, thermic effect of food, physical activity energy expenditure), substrate oxidation, diet intake, and body composition. Results: Subjects with low-normal (≤2.5 mU/L) and high-normal (>2.5 mU/L) TSH levels did not differ in any of the outcome measures. However, across the entire group, serum free triiodothyronine (fT3) levels were directly correlated with resting energy expenditure, body mass index (BMI), body fat mass, and visceral fat mass, with clinically relevant variations in these outcomes. Conclusions: Variations in thyroid function within the laboratory reference range have clinically relevant correlations with resting energy expenditure, BMI, and body composition in L-T4-treated subjects. However, salutary effects of higher fT3 levels on energy expenditure may be counteracted by deleterious effects on body weight and composition. Further studies are needed before these outcomes should be used as a basis for altering L-T4 doses in L-T4-treated subjects.
Purpose: It is not clear whether upper limits of the thyrotropin (TSH) reference range should be lowered. This debate can be better informed by investigation of whether variations in thyroid function within the reference range have clinical effects. Thyroid hormone plays a critical role in determining energy expenditure, body mass, and body composition, and therefore clinically relevant variations in these parameters may occur across the normal range of thyroid function. Methods: This was a cross-sectional study of 140 otherwise healthy hypothyroid subjects receiving chronic replacement therapy with levothyroxine (L-T4) who had TSH levels across the full span of the laboratory reference range (0.34 to 5.6 mU/L). Subjects underwent detailed tests of energy expenditure (total and resting energy expenditure, thermic effect of food, physical activity energy expenditure), substrate oxidation, diet intake, and body composition. Results: Subjects with low-normal (≤2.5 mU/L) and high-normal (>2.5 mU/L) TSH levels did not differ in any of the outcome measures. However, across the entire group, serum free triiodothyronine (fT3) levels were directly correlated with resting energy expenditure, body mass index (BMI), body fat mass, and visceral fat mass, with clinically relevant variations in these outcomes. Conclusions: Variations in thyroid function within the laboratory reference range have clinically relevant correlations with resting energy expenditure, BMI, and body composition in L-T4-treated subjects. However, salutary effects of higher fT3 levels on energy expenditure may be counteracted by deleterious effects on body weight and composition. Further studies are needed before these outcomes should be used as a basis for altering L-T4 doses in L-T4-treated subjects.
Authors: Avantika C Waring; Nicolas Rodondi; Stephanie Harrison; Alka M Kanaya; Eleanor M Simonsick; Iva Miljkovic; Suzanne Satterfield; Anne B Newman; Douglas C Bauer Journal: Clin Endocrinol (Oxf) Date: 2012-06 Impact factor: 3.478
Authors: Ashley E Makepeace; Alexandra P Bremner; Peter O'Leary; Peter J Leedman; Peter Feddema; Valdo Michelangeli; John P Walsh Journal: Clin Endocrinol (Oxf) Date: 2008-03-12 Impact factor: 3.478
Authors: A Tropeano; D Corica; S Curatola; A Li Pomi; C Casto; A Alibrandi; G Pepe; T Aversa; M Wasniewska Journal: J Endocrinol Invest Date: 2022-08-20 Impact factor: 5.467
Authors: Agnieszka Adamska; Andrzej Raczkowski; Zofia Stachurska; Marcin Kondraciuk; Adam Jacek Krętowski; Marcin Adamski; Irina Kowalska; Karol Adam Kamiński Journal: J Clin Med Date: 2022-04-11 Impact factor: 4.964
Authors: Min Joo Kim; Sun Wook Cho; Sumin Choi; Dal Lae Ju; Do Joon Park; Young Joo Park Journal: Int J Endocrinol Date: 2018-05-03 Impact factor: 3.257
Authors: Rudolf Hoermann; John E M Midgley; Rolf Larisch; Johannes W Dietrich Journal: Front Endocrinol (Lausanne) Date: 2019-09-26 Impact factor: 5.555